ab bioscience 产品代理

产品分类 > 临床研究 > ab bioscience 产品代理

ab bioscience 产品代理

ABB的核心竞争力是用于免疫肿瘤疾病诊断和治疗应用的生物制剂蛋白质设计。具体而言,我们在治疗学方面的研发重点是能够调节与抗原靶点和效应分子相关的活动的生物制剂。此外,ABB还设计并生产了一组免疫相关蛋白质试剂,可供生物医学研究人员作为研究工具使用。

AB Biosciences(ABB)成立于2007年,一直致力于治疗性生物制剂的工程和蛋白质试剂的研究。凭借数十年的研发经验,ABB的科学家已经为这两类蛋白质的开发搭建了一个高效的平台。重组替代传统IVIG(PRIM计划)是我们在研发一种独特蛋白质药物以替代传统血清衍生IVIG方面的工程专业知识的一个很好的例子。
价格: 0.00

Z-MAB® Next Generation Control Antibody

Checkpoint Proteins

TNFSuperfamily Proteins (Hexa-Ligands)

 

TNF Receptor Superfamily Proteins

Fc Receptors



ABBs core competence is in protein designs of biologics for diagnostic and therapeutic applications of immuno-oncological disorders. Specifically, our R&D for therapeutics is focused on biologics that are capable of modulating activities associated with antigenic targets and effector molecules. In addition, ABB has designed and produced a panel of immune related protein reagents that are available to biomedical researchers as investigational tools.

 

Founded in 2007, AB Biosciences (ABB) has been dedicated to the engineering of therapeutic biologics and research protein reagents. With decades of combined experience in research and development, ABBs scientists have built an efficient platform for the development of these two protein classes. The recombinant replacement of the traditional IVIG (PRIM program) is a great example of our engineering expertise in R&D of an unique protein drug for replacing the traditional serum-derived IVIG.